Google+ Icon Facebook Icon Twitter Icon LinkedIn Icon E-Mail Icon language
80:20 by 2020 header graphic

80:20 By 2020

As the global leader in scalp cooling, we continue to heavily invest in new R&D, funding multi-disciplinary research groups and conducting clinical trials to help improve the efficiency of scalp cooling (the Paxman cold cap) and ultimately raise the success rate of ‘zero hair loss’ from 50:50 to 80:20 by the year 2020.

We are committed to achieving this.

We continue to work with scientists, oncologists, patients and hospitals around the globe to reduce the amount of time required for scalp cooling/cold cap treatment in hospital and ensure all clinicians are armed with the information they need to plan patients’ treatment more efficiently.

As part of this commitment, we have formed an international multi-disciplinary special interest group (SIG) to look into chemotherapy-induced alopecia (CIA) and scalp cooling.


We know scalp cooling works so our aim is to raise the success rate for all patients undergoing chemotherapy so no one ever has to lose their hair as a side effect of cancer.

Richard Paxman, Managing Director

Through grant funding, the SIG group will set up a 930-patient trial across 40 cancer centres to assess the role of scalp cooling on breast cancer patients receiving the most common and effective chemotherapy treatment, FEC-T.

The aim of the research is to find out if scalp cooling for 30 minutes after chemotherapy is as effective at preventing hair loss as the standard 90 minutes. Patients will be asked to measure things such as comfort during cold cap treatment, the amount of hair loss, whether they wear a wig and how their hair or the loss of it is affecting their lives.

In the long run, we are also proposing maintaining a registry of all scalp cooling patients in the UK, in order to undertake epidemiological studies of large groups of scalp cooling patients to track their long-term health.

As well as this patient-focused research, we have also undertaken a series of clinical trials in the UK, the US, Germany and Austria and are also developing a third-generation of the cold cap to ensure it fits people’s heads more efficiently.

We are committed to working globally with clinicians and patients to achieve this, and are doing everything possible to understand alopecia and improve scalp cooling for the hundreds of people who use it every day. We are committed to ensuring that everyone undergoing chemotherapy treatment keeps their hair and we will not stop until we achieve zero hair loss.

Future updates on progress will appear here.

Back to top